Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 3Phase 1/2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 7

Sponsor

Cancer Type

Breast 4Tumor-Agnostic 2Thoracic 1Sarcoma 1

Conditions

Breast Neoplasms 36Neoplasm Metastasis 10Neoplasms 7Brain Neoplasms 4Triple Negative Breast Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Advanced Malignant Solid Tumors 3Stomach Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Thrombocytosis 1Solid Tumor 1Salivary Gland Neoplasms 1Recurrence 1Rare Tumour 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pathologic Complete Response 1Neuroma, Acoustic 1Neurofibromatosis 2 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Meningioma 1Malignant Female Reproductive System Neoplasm 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Interventional × Neoplasms × neratinib × Clear all
NCT01042379 2026-05-06

I-SPY

QuantumLeap Healthcare Collaborative

Phase 2 Recruiting
5,000 enrolled
BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT01953926 2024-03-12

SUMMIT

Puma Biotechnology, Inc.

Phase 2 Terminated
582 enrolled 27 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms

NCT00838539 2018-09-18

Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
63 enrolled 26 charts
Tumor-Agnostic

Neoplasms

NCT00146172 2018-09-17

Study Evaluating HKI-272 in Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
73 enrolled 20 charts
Breast

Breast Neoplasms, Neoplasms

NCT00397046 2018-09-14

A Study Of The Safety And Tolerability Of HKI-272 Administered Orally To Japanese Subjects With Advanced Solid Tumors

Puma Biotechnology, Inc.

Phase 1 Completed
21 enrolled 13 charts
Tumor-Agnostic

Neoplasms

NCT00300781 2018-08-14

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

Puma Biotechnology, Inc.

Phase 2 Completed
136 enrolled 11 charts
Breast

Breast Neoplasms, Neoplasms

NCT00445458 2018-07-26

A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer

Puma Biotechnology, Inc.

Phase 1/2 Completed
110 enrolled 13 charts
Breast

Breast Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡